Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603)
暂无分享,去创建一个
Thomas J. Smith | P. Novotny | R. Leon-Ferre | C. Loprinzi | K. Rowland | K. Ruddy | M. Graham | N. Le-Lindqwister | S. Faubion | D. Flora | C. Dakhil | E. Wolfe
[1] P. Neven,et al. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Thomas J. Smith,et al. Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men. , 2018, The New England journal of medicine.
[3] M. Whirl‐Carrillo,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy , 2018, Clinical pharmacology and therapeutics.
[4] Carol Brayne,et al. Anticholinergic drugs and risk of dementia: case-control study , 2018, BMJ.
[5] S. Morrow,et al. Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis , 2018, Journal of the Neurological Sciences.
[6] Yu-wan Yang,et al. Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus , 2017, PloS one.
[7] J. Simon,et al. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial , 2016, Menopause.
[8] P. Puech-Leão,et al. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. , 2012, Journal of vascular surgery.
[9] O. Dalesio,et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Guralnick,et al. Antimuscarinic Drugs: Review of the Cognitive Impact When Used to Treat Overactive Bladder in Elderly Patients , 2011, Current urology reports.
[11] Craig G. Crandall,et al. Mechanisms of cutaneous vasodilation during the postmenopausal hot flash , 2011, Menopause.
[12] A. LaCroix,et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. , 2011, JAMA.
[13] Dawn L Hershman,et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Sloan,et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Loprinzi,et al. A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors. , 2010 .
[16] C. Loprinzi,et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] P. Novotny,et al. Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration , 2009, Menopause.
[18] P. Novotny,et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A M Thompson,et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer , 2008, British Journal of Cancer.
[20] U. Ebinger,et al. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin , 2008, International journal of clinical practice.
[21] G. Constantine,et al. Efficacy and Tolerability of Desvenlafaxine Succinate Treatment for Menopausal Vasomotor Symptoms: A Randomized Controlled Trial , 2008, Obstetrics and gynecology.
[22] M. Lock,et al. Oxybutynin for refractory hot flashes in cancer patients , 2007, Menopause.
[23] J. Tice,et al. Ineffectiveness of Sertraline for Treatment of Menopausal Hot Flushes: A Randomized Controlled Trial , 2007, Obstetrics and gynecology.
[24] P. Novotny,et al. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Xin Wang,et al. Stepwise Gatekeeping Procedures in Clinical Trial Applications , 2006, Biometrical journal. Biometrische Zeitschrift.
[26] Zeruesenay Desta,et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment , 2006, Clinical pharmacology and therapeutics.
[27] J. Senf,et al. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population , 2006, Menopause.
[28] D. Guzick,et al. Gabapentin, Estrogen, and Placebo for Treating Hot Flushes: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.
[29] J. Sloan,et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Lovato,et al. Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen , 2006, The breast journal.
[31] T. Sweeney,et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial , 2005, The Lancet.
[32] David A. Flockhart,et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.
[33] E. Vittinghoff,et al. Management of Postmenopausal Hot Flushes With Venlafaxine Hydrochloride: A Randomized, Controlled Trial , 2005, Obstetrics and gynecology.
[34] E. Freeman,et al. Acute consequences of the menopausal transition: the rise of common menopausal symptoms. , 2004, Endocrinology and metabolism clinics of North America.
[35] A. Maclennan,et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. , 2004, The Cochrane database of systematic reviews.
[36] Zeruesenay Desta,et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.
[37] V. Stearns,et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. , 2003, JAMA.
[38] G. Norman,et al. Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.
[39] K. Kieburtz,et al. Gabapentin's Effects on Hot Flashes in Postmenopausal Women: A Randomized Controlled Trial , 2003, Obstetrics and gynecology.
[40] C. Isaacs,et al. Hot flushes , 2002, The Lancet.
[41] E. Perez,et al. Phase III evaluation of fluoxetine for treatment of hot flashes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] F. Belpaire,et al. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. , 2002, Current drug metabolism.
[43] P. Novotny,et al. Methodologic lessons learned from hot flash studies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] J. Carpenter. The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. , 2001, Journal of pain and symptom management.
[45] W. Dimpfel,et al. Effects of Tolterodine, Trospium Chloride, and Oxybutynin on the Central Nervous System , 2001, Journal of clinical pharmacology.
[46] Debra L Barton,et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial , 2000, The Lancet.
[47] R. Freedman,et al. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. , 1999, American journal of obstetrics and gynecology.
[48] Y. Nordenberg,et al. The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women. , 1996, Israel journal of medical sciences.
[49] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[50] Yoshiaki Nakamura,et al. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer , 2014, Breast Cancer.
[51] C. Tannenbaum,et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. , 2012, Drugs & aging.
[52] G. Constantine,et al. REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause , 2009 .
[53] R. Bloigu,et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study , 2005, Menopause.
[54] W. Dimpfel,et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers , 2004, European Journal of Clinical Pharmacology.
[55] M. Andrykowski,et al. Hot flashes and related outcomes in breast cancer survivors and matched comparison women. , 2002, Oncology nursing forum.
[56] T. Hughes-Davies. Megestrol acetate for the prevention of hot flashes. , 1995, The New England journal of medicine.
[57] J. O'fallon,et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.